Takeda Pharmaceutical (TAK) Non-Current Deferred Tax Liability (2017 - 2026)

Takeda Pharmaceutical's Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $170.9 million for Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 25.82% year-over-year to $170.9 million in Q1 2026; TTM through Mar 2026 was $170.9 million, a 25.82% decrease from a year earlier, with the FY2026 full-year figure at $178.1 million, down 22.84% from the prior year.
• Non-Current Deferred Tax Liability slipped to $170.9 million in Q1 2026 per TAK's latest filing, from $203.3 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $3.9 billion in Q1 2022 and bottomed at $170.9 million in Q1 2026.
• The 5-year median for Non-Current Deferred Tax Liability is $767.7 million (2024), against an average of $1.3 billion.
• Across the five-year window, Non-Current Deferred Tax Liability sank 81.87% in 2024 and decreased 17.97% in 2025, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $2.8 billion in 2022, then plunged by 67.29% to $900.0 million in 2023, then tumbled by 72.47% to $247.8 million in 2024, then retreated by 17.97% to $203.3 million in 2025, then declined by 15.92% to $170.9 million in 2026.
• Per Business Quant, the three latest TAK Non-Current Deferred Tax Liability figures stand at $170.9 million (Q1 2026), $203.3 million (Q4 2025), and $224.2 million (Q3 2025).